These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 130433)

  • 21. Selected hemostatic abnormalities associated with neoplastic disease.
    Ito R; Statland BE
    Clin Lab Med; 1982 Sep; 2(3):599-625. PubMed ID: 6814812
    [No Abstract]   [Full Text] [Related]  

  • 22. [Diagnostic significance of proteolytic breakdown products of fibrinogen and fibrin].
    Heene DL; Genth K
    Internist (Berl); 1984 Feb; 25(2):93-101. PubMed ID: 6231262
    [No Abstract]   [Full Text] [Related]  

  • 23. Hemostasis and malignancy.
    Francis JL; Biggerstaff J; Amirkhosravi A
    Semin Thromb Hemost; 1998; 24(2):93-109. PubMed ID: 9579631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Heparin therapy in the disseminated intravascular coagulation syndrome. Considerations on 2 cases].
    Cutcudache C; Pavelescu I; Brăilescu G; Bălan A; Boldescu G; Lachi D
    Med Interna (Bucur); 1971 Jun; 23(6):729-40. PubMed ID: 5565661
    [No Abstract]   [Full Text] [Related]  

  • 25. [Comparative study of various rapid methods of determining fibrinogen transformation products in the diagnosis of intravascular coagulation and fibrinolysis].
    Lychev VG; Momot AP; Cherkashin GV
    Ter Arkh; 1984; 56(6):106-9. PubMed ID: 6474366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Changes in hemostasis associated with metastatic processes].
    Bastida E; Ordinas A
    Med Clin (Barc); 1983 Mar; 80(8):376-80. PubMed ID: 6343735
    [No Abstract]   [Full Text] [Related]  

  • 27. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features.
    Sack GH; Levin J; Bell WR
    Medicine (Baltimore); 1977 Jan; 56(1):1-37. PubMed ID: 834136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The prevention of the hypercoagulation syndrome during the combined treatment of lung cancer patients using artificial hyperglycemia].
    Fradkin SZ; Zhavrid EA; Prokhorova VI; Nodel'son SE; Khodina TV; Antipova LI; Demidchik IuE
    Vopr Onkol; 1991; 37(3):321-9. PubMed ID: 2031327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of high-dose progestogen on hemostatic properties of blood in patients with endometrial cancer.
    Kaibara M; Watanabe T; Ooka F; Liang SG; Aisaka K; Okinaga S
    Clin Hemorheol Microcirc; 2001; 24(2):93-9. PubMed ID: 11381184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disseminated intravascular coagulation and the balance between blood coagulation and fibrinolysis.
    Astrup T; Jespersen J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):407-15. PubMed ID: 6083904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Disseminated intravascular coagulation syndrome (D.I.C.) and carcinoma of the prostate (author's transl)].
    Becopoulos T; Kranides A; Mandalaki-Yianitsiotis T; Louizou K; Panagiotopoulou E; Dimopoulos C
    J Urol (Paris); 1980; 86(6):467-70. PubMed ID: 6160184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The significance of the fibrin/fibrinogen degradation product in serum of carcinoma patients with hematogenous metastasis.
    Imaoka S; Sasaki Y; Iwanaga T; Terasawa T
    Cancer; 1986 Oct; 58(7):1488-92. PubMed ID: 3742466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Abnormalities of coagulation and fibrinolysis in patients with neoplasms (author's transl)].
    Martínez Canaveri AA; Carreras LO; Abate NH; Taffuni de De Nigris M; Fustinoni O
    Sangre (Barc); 1977; 22(5):332-63. PubMed ID: 905936
    [No Abstract]   [Full Text] [Related]  

  • 34. [Significance of fibrinopeptide A as an indicator for coagulative analysis in thrombotic diseases].
    Murakoshi T
    Hokkaido Igaku Zasshi; 1982 May; 57(3):351-63. PubMed ID: 6957368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathogenesis of disseminated intravascular coagulation.
    Larrieu MJ
    Southeast Asian J Trop Med Public Health; 1979 Sep; 10(3):321-4. PubMed ID: 515795
    [No Abstract]   [Full Text] [Related]  

  • 36. [Determination of fibrinogen-fibrin degradation factors in neoplasms].
    Petrella V; Massara G; Parachini F; Silvera F; Cantone R
    Minerva Med; 1988 Feb; 79(2):117-21. PubMed ID: 3352945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proceedings: Inhibition of experimental metastases by defibrination.
    Jagelman DG
    Ann R Coll Surg Engl; 1974 Jun; 54(6):271. PubMed ID: 4833776
    [No Abstract]   [Full Text] [Related]  

  • 38. [Fibrin degradation products (FDP) and fibrinolytic activity of blood in various acute and chronic diseases].
    Kotschy M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1976; 103(3):425-30. PubMed ID: 63429
    [No Abstract]   [Full Text] [Related]  

  • 39. Detection of hypercoagulable states with protamine sulphate tests.
    Lipinski B
    Acta Univ Carol Med Monogr; 1972; 52():185-8. PubMed ID: 4273929
    [No Abstract]   [Full Text] [Related]  

  • 40. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study.
    Sallah S; Wan JY; Nguyen NP; Hanrahan LR; Sigounas G
    Thromb Haemost; 2001 Sep; 86(3):828-33. PubMed ID: 11583315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.